…
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.43M | -4.32M | -2.09M | -3.91M | -2.18M |
| Net income | -2.43M | -4.32M | -2.09M | -3.91M | -2.18M |
| Selling general administrative | 1.70M | 3.24M | 1.16M | 1.07M | 1.50M |
| Gross profit | -0.64M | -0.70M | -0.40M | - | - |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Ebit | - | - | - | -3.91M | -2.18M |
| Ebitda | - | - | - | -3.91M | -2.18M |
| Operating income | -2.42M | -4.32M | -2.09M | -3.91M | -2.18M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.01M | 0.00M |
| Net interest income | -0.00M | -0.00M | -0.00M | -0.01M | -0.00M |
| Non recurring | - | - | - | 2.03M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 2.42M | 4.32M | 2.09M | 3.91M | 2.18M |
| Cost of revenue | 0.64M | 0.70M | 0.40M | - | - |
| Total other income expense net | - | - | - | -2.03M | -0.68M |
| Net income from continuing ops | -2.43M | -4.32M | -2.09M | -3.91M | -2.18M |
| Net income applicable to common shares | - | - | - | -3.91M | -2.18M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.02M | 0.01M | 0.00M | 0.00M | 0.00M |
| Total liab | 2.32M | 1.48M | 1.41M | 1.07M | 0.47M |
| Total stockholder equity | -2.30M | -1.46M | -1.41M | -1.07M | -0.46M |
| Other current liab | - | - | - | 0.11M | 0.14M |
| Common stock | - | - | - | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -17.86M | -15.43M | -11.11M | -9.02M | -5.10M |
| Cash | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Total current liabilities | 2.32M | 1.47M | 1.41M | 1.07M | 0.47M |
| Net debt | 0.03M | 0.04M | 0.05M | 0.05M | 0.07M |
| Short term debt | - | - | - | 0.05M | - |
| Short long term debt | 0.05M | 0.05M | 0.05M | 0.05M | 0.07M |
| Property plant equipment | - | - | - | 0.00M | - |
| Total current assets | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Net tangible assets | - | - | - | -1.07M | -0.46M |
| Accounts payable | 1.08M | 0.92M | 0.88M | 0.91M | 0.25M |
| Common stock total equity | - | - | - | 0.00M | - |
| Retained earnings total equity | - | - | - | -9.02M | - |
| Non current assets total | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital lease obligations | 0.01M | 0.01M | 0.00M | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | 0.00M | -0.00M | - |
| Change to liabilities | - | - | - | 0.23M | 0.11M |
| Total cashflows from investing activities | - | - | - | -0.00M | -0.00M |
| Net borrowings | - | - | - | 0.11M | 0.07M |
| Total cash from financing activities | 0.57M | 0.75M | 0.45M | 0.19M | 1.17M |
| Change to operating activities | - | - | - | - | 0.05M |
| Net income | -2.43M | -4.32M | -2.09M | -3.91M | -2.18M |
| Change in cash | 0.01M | 0.01M | -0.00M | -0.00M | 0.00M |
| Begin period cash flow | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| End period cash flow | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Total cash from operating activities | -0.56M | -0.74M | -0.45M | -0.20M | -1.17M |
| Issuance of capital stock | 0.40M | 0.50M | 0.00M | 0.06M | 1.08M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Sale purchase of stock | - | - | - | 0.09M | - |
| Change to netincome | - | - | - | 3.71M | 0.86M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Cash and cash equivalents changes | - | - | - | -0.00M | - |
| Change in working capital | 0.17M | 0.19M | 0.41M | 0.23M | 0.16M |
| Stock based compensation | 1.04M | 2.61M | 0.66M | 0.26M | 0.31M |
| Other non cash items | 0.66M | 0.78M | 0.56M | 3.23M | 0.55M |
| Free cash flow | -0.56M | -0.74M | -0.45M | -0.20M | -1.17M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RTGN RetinalGenix Technologies Inc |
- -% |
3.99 | - | - | - | - | -42.68 |
| ABT Abbott Laboratories |
-2.82 2.62% |
104.63 | 25.97 | 17.24 | 3.57 | 3.20 | 16.75 |
| MDT Medtronic PLC |
- -% |
102.32 | 26.60 | 15.87 | 3.35 | 2.08 | 14.12 |
| SYK Stryker Corporation |
6.55 2.11% |
317.27 | 29.23 | 16.86 | 4.18 | 4.51 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.26 | 39.57 | 21.32 | 3.01 | 3.29 | 16.92 |
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
409 Apollo Beach Boulevard, Apollo Beach, FL, United States, 33572
415 578 9583
| Name | Title | Year Born |
|---|---|---|
| Dr. Jerry Katzman | CEO, Pres & Director | 1953 |
| Dr. Jerry Katzman M.D. | CEO, President, Interim CFO & Chairman | 1953 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.